It is time to stop turning a blind eye to what is going on in Zimbabwe, where the government has shown over and over that it is violent and willing to do anything to stay in power, writes Jamie Mighti.Am I my brother's keeper?This moral question is one that often confronts most people at some…
Some hospitals in states where coronavirus cases are surging are running out of beds. Doctors and nurses, who watched COVID-19 hit New York City hard, are concerned about what's next for their communities.Five front-line medical workers from Texas, Florida, Alabama and California, spoke to CBS News senior medical correspondent Dr. Tara Narula about their fears and…
Former Food and Drug Administration commissioner Scott Gottlieb said Sunday that some states in the U.S. reopened businesses too early, leading to surges in coronavirus cases across the country. “I think that they felt they were out of the woods after that first wave passed, but this has really been a regional experience in the United…
on. People got complacent. People got a little bit overly confident in our ability to manage, You know more normally and people started to act like it was summer. They started to act like they wanted to go back to parties and do lots of big things like that. And it's coming back and it's…
Contact tracers at work in a Houston contact tracing facility. | AP Photo/David J. Phillip Severe shortages of public health workers to track disease spread helped fuel coronavirus spikes in states like Florida, Texas and Arizona and could make it harder to stamp out new hot spots. Florida Gov. Ron DeSantis has about 10 percent…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f